241 related articles for article (PubMed ID: 32019783)
1. A Randomized Trial of Empagliflozin to Increase Plasma Sodium Levels in Patients with the Syndrome of Inappropriate Antidiuresis.
Refardt J; Imber C; Sailer CO; Jeanloz N; Potasso L; Kutz A; Widmer A; Urwyler SA; Ebrahimi F; Vogt DR; Winzeler B; Christ-Crain M
J Am Soc Nephrol; 2020 Mar; 31(3):615-624. PubMed ID: 32019783
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Single- and multiple-dose Once-daily Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Chinese Patients With Type 2 Diabetes Mellitus.
Zhao X; Cui Y; Zhao S; Lang B; Broedl UC; Salsali A; Pinnetti S; Macha S
Clin Ther; 2015 Jul; 37(7):1493-502. PubMed ID: 26101175
[TBL] [Abstract][Full Text] [Related]
3. Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial.
Jensen J; Omar M; Kistorp C; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Faber J; Malik ME; Fosbøl EL; Bruun NE; Forman JL; Jensen LT; Møller JE; Schou M
Lancet Diabetes Endocrinol; 2021 Feb; 9(2):106-116. PubMed ID: 33357505
[TBL] [Abstract][Full Text] [Related]
4. Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
Mordi NA; Mordi IR; Singh JS; McCrimmon RJ; Struthers AD; Lang CC
Circulation; 2020 Nov; 142(18):1713-1724. PubMed ID: 32865004
[TBL] [Abstract][Full Text] [Related]
5. Urea in cancer patients with chronic SIAD-induced hyponatremia: Old drug, new evidence.
Nervo A; D'Angelo V; Rosso D; Castellana E; Cattel F; Arvat E; Grossi E
Clin Endocrinol (Oxf); 2019 Jun; 90(6):842-848. PubMed ID: 30868608
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes.
Heise T; Jordan J; Wanner C; Heer M; Macha S; Mattheus M; Lund SS; Woerle HJ; Broedl UC
Clin Ther; 2016 Oct; 38(10):2265-2276. PubMed ID: 27692976
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes.
Heise T; Seewaldt-Becker E; Macha S; Hantel S; Pinnetti S; Seman L; Woerle HJ
Diabetes Obes Metab; 2013 Jul; 15(7):613-21. PubMed ID: 23356556
[TBL] [Abstract][Full Text] [Related]
8. Fluid Restriction Therapy for Chronic SIAD; Results of a Prospective Randomized Controlled Trial.
Garrahy A; Galloway I; Hannon AM; Dineen R; O'Kelly P; Tormey WP; O'Reilly MW; Williams DJ; Sherlock M; Thompson CJ
J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32879954
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Furosemide, Oral Sodium Chloride, and Fluid Restriction for Treatment of Syndrome of Inappropriate Antidiuresis (SIAD): An Open-label Randomized Controlled Study (The EFFUSE-FLUID Trial).
Krisanapan P; Vongsanim S; Pin-On P; Ruengorn C; Noppakun K
Am J Kidney Dis; 2020 Aug; 76(2):203-212. PubMed ID: 32199708
[TBL] [Abstract][Full Text] [Related]
10. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
[TBL] [Abstract][Full Text] [Related]
11. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial.
Packer M; Anker SD; Butler J; Filippatos G; Ferreira JP; Pocock SJ; Sattar N; Brueckmann M; Jamal W; Cotton D; Iwata T; Zannad F;
J Am Coll Cardiol; 2021 Mar; 77(11):1381-1392. PubMed ID: 33736819
[TBL] [Abstract][Full Text] [Related]
12. Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial.
Jensen J; Omar M; Kistorp C; Poulsen MK; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Faber J; Fosbøl EL; Bruun NE; Brønd JC; Forman JL; Videbæk L; Møller JE; Schou M
Am Heart J; 2020 Oct; 228():47-56. PubMed ID: 32798787
[TBL] [Abstract][Full Text] [Related]
13. Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial.
Shimada A; Hanafusa T; Yasui A; Lee G; Taneda Y; Sarashina A; Shiki K; George J; Soleymanlou N; Marquard J
Diabetes Obes Metab; 2018 Sep; 20(9):2190-2199. PubMed ID: 29766633
[TBL] [Abstract][Full Text] [Related]
14. Empagliflozin as add-on to metformin in people with Type 2 diabetes.
Merker L; Häring HU; Christiansen AV; Roux F; Salsali A; Kim G; Meinicke T; Woerle HJ; Broedl UC;
Diabet Med; 2015 Dec; 32(12):1555-67. PubMed ID: 26031566
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
Macha S; Mattheus M; Halabi A; Pinnetti S; Woerle HJ; Broedl UC
Diabetes Obes Metab; 2014 Mar; 16(3):215-22. PubMed ID: 23859488
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
Chen S; Zhao JJ; Tong NW; Guo XH; Qiu MC; Yang GY; Liu ZM; Ma JH; Zhang ZW; Gu F
J Clin Pharmacol; 2014 Dec; 54(12):1362-7. PubMed ID: 24906029
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus.
Mondick J; Riggs M; Kaspers S; Soleymanlou N; Marquard J; Nock V
J Clin Pharmacol; 2018 May; 58(5):640-649. PubMed ID: 29251772
[TBL] [Abstract][Full Text] [Related]
18. Empagliflozin after Acute Myocardial Infarction.
Butler J; Jones WS; Udell JA; Anker SD; Petrie MC; Harrington J; Mattheus M; Zwiener I; Amir O; Bahit MC; Bauersachs J; Bayes-Genis A; Chen Y; Chopra VK; Figtree G; Ge J; Goodman SG; Gotcheva N; Goto S; Gasior T; Jamal W; Januzzi JL; Jeong MH; Lopatin Y; Lopes RD; Merkely B; Parikh PB; Parkhomenko A; Ponikowski P; Rossello X; Schou M; Simic D; Steg PG; Szachniewicz J; van der Meer P; Vinereanu D; Zieroth S; Brueckmann M; Sumin M; Bhatt DL; Hernandez AF
N Engl J Med; 2024 Apr; 390(16):1455-1466. PubMed ID: 38587237
[TBL] [Abstract][Full Text] [Related]
19. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
[TBL] [Abstract][Full Text] [Related]
20. Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: interim analysis from a post-marketing surveillance study.
Kaku K; Chin R; Naito Y; Iliev H; Ikeda R; Ochiai K; Yasui A
Expert Opin Drug Saf; 2020 Feb; 19(2):211-221. PubMed ID: 31769309
[No Abstract] [Full Text] [Related]
[Next] [New Search]
